About Indigo Biosciences
Indigo Biosciences is a company based in State College (United States) founded in 2005. Indigo Biosciences has raised $1.28 million across 4 funding rounds from investors including LSG Investments, Allied Growth Strategies & Management and iNetworks. The company has 17 employees as of December 31, 2023. Indigo Biosciences offers products and services including FGFR3 Reporter Assay Kit, DRD1 Reporter Assay Kit, GCGR Reporter Assay Kit, GIPR Reporter Assay Kit, and GLP-1R Reporter Assay Kit. Indigo Biosciences operates in a competitive market with competitors including Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.
- Headquarter State College, United States
- Employees 17 as on 31 Dec, 2023
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Indigo Biosciences, Incorporated
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.28 M (USD)
in 4 rounds
-
Latest Funding Round
$500 K (USD), Series B
Jun 28, 2016
-
Investors
LSG Investments
& 2 more
-
Employee Count
17
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Indigo Biosciences
Indigo Biosciences offers a comprehensive portfolio of products and services, including FGFR3 Reporter Assay Kit, DRD1 Reporter Assay Kit, GCGR Reporter Assay Kit, GIPR Reporter Assay Kit, and GLP-1R Reporter Assay Kit.
Kit for screening activity against Human Fibroblast Growth Factor Receptor.
Kit for screening activity against Human Dopamine Receptor D1.
Kit for screening activity against Human Glucagon Receptor.
Kit for screening activity against Human Gastric Inhibitory Polypeptide Receptor.
Kit for screening activity against Human Glucagon-Like Peptide-1 Receptor.
People of Indigo Biosciences
Unlock access to complete
Unlock access to complete
Leadership Team
8 people
Sales and Marketing
2 people
Scientist Team
2 people
CTO Team
1 people
Unlock access to complete
Funding Insights of Indigo Biosciences
Indigo Biosciences has successfully raised a total of $1.28M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $500 thousand completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Indigo Biosciences
Indigo Biosciences has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include LSG Investments, Allied Growth Strategies & Management and iNetworks.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in life sciences technologies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
iNetworks is engaged in private equity investments and operational support.
|
Locked | Locked | Locked |
Investor details for Indigo Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Indigo Biosciences
Investment portfolio details for Indigo Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Indigo Biosciences
Detailed financials for Indigo Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Indigo Biosciences Comparisons
Peer comparison for Indigo Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Indigo Biosciences
Indigo Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of in-vitro diagnostic products for the detection of cancer
|
|
| Locked | Locked | Locked |
Real-time cell analyzers are developed for oxygen consumption monitoring.
|
|
| Locked | Locked | Locked |
Kiyatec is focused on revolutionizing cancer care through predictive platforms.
|
|
| Locked | Locked | Locked |
Cell-based assays for drug discovery are developed via CMOS platform.
|
|
| Locked | Locked | Locked |
3D cell culture products are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Metastatic cancer properties are targeted by Remedy Plan's containment therapy.
|
Detailed competitors of Indigo Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indigo Biosciences
Complete news archive for Indigo Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indigo Biosciences
Indigo Biosciences was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Indigo Biosciences is headquartered in State College, United States. It is registered at State College, Pennsylvania, United States.
Indigo Biosciences is a funded company, having raised a total of $1.28M across 4 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Indigo Biosciences is 17.
Founded in 2005 and based in State College, United States, Indigo Biosciences operates in the biotechnology sector. Nuclear receptor-specific reporter assays are developed using engineered cells preserved through the proprietary CryoMite process for extended storage and shipping. Cell-based assays for therapeutic drug target evaluation are offered, along with related in vitro toxicology services, enabling on-demand use in research applications.
Indigo Biosciences's top competitors include CytoTronics, Kiyatec and Remedy Plan.
Indigo Biosciences offers FGFR3 Reporter Assay Kit, DRD1 Reporter Assay Kit, GCGR Reporter Assay Kit, GIPR Reporter Assay Kit, and GLP-1R Reporter Assay Kit.
Indigo Biosciences has 3 investors. Key investors include LSG Investments, Allied Growth Strategies & Management, and iNetworks.